Key facts
- Allergen Alert’s last known valuation is $12.4M (Oct 2025).
- It has raised $4.2M; the latest was Early Stage VC ($4.2M) in Oct 2025.
- Notable investors include BioMérieux, Demea Sustainable Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Allergen Alert
- ·The full record, as it builds
Funding rounds
No funding rounds for Allergen Alert are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allergen Alert
Developer of a real-time food allergen testing system designed to change the lives of allergic patients by reducing the risk of exposure to food allergens. The company offers a portable, real-time test for food allergens, enabling customers to test their plate and significantly reduce the risk of exposure to food allergens.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Messimy, France
- Founded
- 2024
- Employees
- 6
- Website
- allergen-alert.com/
- Ownership
- Privately Held (backing)
Allergen Alert doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allergen Alert shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allergen Alert in its N-PORT filings yet. We sweep new filings monthly.